Lataa...
Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues
Anti-angiogenic therapies are an important class of anti-cancer treatment drugs. However, their efficacy is limited to certain tumors and would benefit from identifying a biomarker predictive of therapeutic response. TP53 (tumor protein p53) is a tumor suppressor gene frequently mutated in cancer an...
Tallennettuna:
| Julkaisussa: | Cancer Biol Ther |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Taylor & Francis
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7012180/ https://ncbi.nlm.nih.gov/pubmed/31564192 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2019.1665956 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|